New pathways convert sugars to pyrrolamides in Gram-positive bacteria, revealing unique metabolic strategies.
Pyrrolamides, defined by a pyrrole-2-carboxamide core, represent a family of natural products produced by Streptomyces species. They exhibit potent yet promiscuous bioactivities, including antimicrobial, antifungal, antiviral, and anticancer effects. The characteristic pyrrole moiety is derived from 4-acetamidopyrrole-2-carboxylate, which was previously proposed to originate most likely from N-acetylglucosamine-1-phosphate. This unusual transformation of a primary metabolite sugar into an aromatic peptide building block is of interest mechanistically; however, the pathway preceding pyrrole formation remains unclear. We herein report the discovery of manlipyrrolamides A-F from Bacillus manliponensis, a new class of pyrrolamides with distinctive structural features. Gene disruption and in vitro assays allowed us to identify the functions of key enzymes in the pyrrole formation pathway. Man17, a nucleotidyltransferase, functions as a gatekeeper that activates the precursor N-acetylglucosamine-1-phosphate, through guanosine diphosphate (GDP) derivatization for subsequent modifications. Man18, a glycosyltransferase-like enzyme, and Man15, a glycoside hydrolase-like enzyme, function as a hydrolase and dehydratase, respectively, forming a pyrrole from a mature GDP-linked sugar. After pyrrole formation, a xanthine dehydrogenase-like enzyme complex is utilized in oxidation to produce carboxylate, distinct from the previously proposed Streptomyces pathway. The pathway-specific enzyme Man15, which is widely distributed in Gram-positive bacteria, is encoded in diverse biosynthetic gene clusters, indicating that this unprecedented transformation is utilized for unknown classes of pyrrolamides. The use of a GDP derivative suggests an orthogonal strategy distinct from that of the canonical UDP-linked sugar pathway. The present study reveals novel sugar skeletal conversion in secondary metabolism, which provides novel insights into bacterial metabolic strategies.
No takes yet. Share an insight, caveat, or question.
Kanki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: